GT201200205A - "analogo peptidico de oxintomodulina" - Google Patents
"analogo peptidico de oxintomodulina"Info
- Publication number
- GT201200205A GT201200205A GT201200205A GT201200205A GT201200205A GT 201200205 A GT201200205 A GT 201200205A GT 201200205 A GT201200205 A GT 201200205A GT 201200205 A GT201200205 A GT 201200205A GT 201200205 A GT201200205 A GT 201200205A
- Authority
- GT
- Guatemala
- Prior art keywords
- oxintomoduline
- peptidal
- analog
- peptide
- oxm
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 101710173663 Glucagon-1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000000813 peptide hormone Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28888409P | 2009-12-22 | 2009-12-22 | |
| US35256910P | 2010-06-08 | 2010-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201200205A true GT201200205A (es) | 2014-04-08 |
Family
ID=43568014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201200205A GT201200205A (es) | 2009-12-22 | 2012-06-20 | "analogo peptidico de oxintomodulina" |
Country Status (26)
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| RU2440097C2 (ru) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| MX2010004297A (es) | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Antagonistas de glucagon. |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| RU2550696C2 (ru) | 2008-12-19 | 2015-05-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Основанные на амидах пролекарства пептидов глюкагонового надсемейства |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| HRP20171801T1 (hr) | 2009-09-28 | 2017-12-29 | Intarcia Therapeutics, Inc. | Brzo uspostavljanje i/ili brzo završavanje uglavnom stabilne primjene lijeka |
| AR079345A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| IN2012DN06437A (cg-RX-API-DMAC7.html) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| EA201390941A1 (ru) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| BR112013030933A2 (pt) * | 2011-06-02 | 2018-04-24 | Prolor Biotech Inc | agonistas do receptor de glp-1/glucágon de ação prolongada |
| PE20140765A1 (es) | 2011-06-10 | 2014-06-14 | Hanmi Science Co Ltd | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos |
| UA125895C2 (uk) | 2011-06-17 | 2022-07-06 | Ханмі Сайенс Ко., Лтд. | КОН'ЮГАТ, ЩО МІСТИТЬ ПОХІДНУ ОКСИНТОМОДУЛІНУ ТА Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ, ТА ЙОГО ЗАСТОСУВАННЯ |
| EA031230B1 (ru) | 2011-06-22 | 2018-12-28 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Агонисты глюкагонового рецептора/glp-1-рецептора |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| CN103957927B (zh) | 2011-11-17 | 2016-11-09 | 印第安纳大学研究及科技有限公司 | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 |
| MX2014012625A (es) * | 2012-04-19 | 2015-05-15 | Opko Biolog Ltd | Variantes de oxintomodulina de accion prolongada y metodos para su produccion. |
| SG11201408054RA (en) | 2012-06-04 | 2015-01-29 | Opko Biolog Ltd | Pegylated oxm variants |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014073842A1 (en) | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| RS57531B1 (sr) | 2012-12-21 | 2018-10-31 | Sanofi Sa | Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti |
| AU2014231330A1 (en) * | 2013-03-15 | 2015-10-01 | Adaerata, Limited Partnership | Small molecule modulators of PCSK9 and methods of use thereof |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US12459982B2 (en) | 2014-12-10 | 2025-11-04 | Opko Biologistics Ltd. | Methods of producing long acting CTP-modified growth hormone polypeptides |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| RU2760007C2 (ru) | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Полипептиды, селективные к рецепторам глюкагона, и способы их применения |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| SG11201900279UA (en) | 2016-07-11 | 2019-02-27 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
| WO2018129058A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| CN108299554B (zh) * | 2017-01-13 | 2021-05-25 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素类似物 |
| CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素（oxm）类似物及其应用 |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| KR102154959B1 (ko) * | 2020-04-29 | 2020-09-10 | 동아에스티 주식회사 | 지속형 glp-1 및 글루카곤 수용체 이중작용제 |
| WO2025169190A2 (en) | 2024-02-06 | 2025-08-14 | Opko Biologics Ltd. | Modified oxyntomodulin and methods of use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5445090A (en) | 1991-07-25 | 1995-08-29 | Mim Industries, Inc. | Interchangeable clamp for use in a sewing machine |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| JP4861586B2 (ja) | 1999-12-22 | 2012-01-25 | ネクター セラピューティックス | 水溶性ポリマーの立体的に妨害される誘導体 |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7557183B2 (en) | 2003-03-19 | 2009-07-07 | Eli Lilly And Company | Polyethylene glycol linked GLP-1 compounds |
| CN101166545B (zh) | 2005-05-13 | 2011-06-15 | 伊莱利利公司 | Glp-1聚乙二醇化的化合物 |
| WO2006134340A2 (en) * | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| EP1991574B1 (en) * | 2006-02-22 | 2016-10-12 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
-
2010
- 2010-12-09 AR ARP100104554A patent/AR079344A1/es unknown
- 2010-12-10 TW TW099143355A patent/TWI451873B/zh not_active IP Right Cessation
- 2010-12-15 KR KR1020127016092A patent/KR101399692B1/ko not_active Expired - Fee Related
- 2010-12-15 BR BR112012017054A patent/BR112012017054A2/pt not_active IP Right Cessation
- 2010-12-15 ES ES10799178.8T patent/ES2512141T3/es active Active
- 2010-12-15 US US12/968,388 patent/US8415296B2/en active Active
- 2010-12-15 AU AU2010341650A patent/AU2010341650B2/en not_active Ceased
- 2010-12-15 EP EP10799178.8A patent/EP2515927B1/en active Active
- 2010-12-15 CA CA2784668A patent/CA2784668C/en active Active
- 2010-12-15 PE PE2012000855A patent/PE20121721A1/es not_active Application Discontinuation
- 2010-12-15 WO PCT/US2010/060380 patent/WO2011087671A1/en not_active Ceased
- 2010-12-15 JP JP2012546033A patent/JP5717758B2/ja active Active
- 2010-12-15 NZ NZ600732A patent/NZ600732A/en not_active IP Right Cessation
- 2010-12-15 CN CN201080058422.4A patent/CN102665752B/zh active Active
- 2010-12-15 SG SG2012046223A patent/SG181872A1/en unknown
- 2010-12-15 EA EA201290557A patent/EA201290557A1/ru unknown
- 2010-12-15 UA UAA201207074A patent/UA106399C2/ru unknown
- 2010-12-15 MX MX2012007449A patent/MX2012007449A/es active IP Right Grant
-
2012
- 2012-06-14 MA MA34969A patent/MA33826B1/fr unknown
- 2012-06-14 TN TNP2012000303A patent/TN2012000303A1/en unknown
- 2012-06-20 DO DO2012000175A patent/DOP2012000175A/es unknown
- 2012-06-20 GT GT201200205A patent/GT201200205A/es unknown
- 2012-06-20 EC ECSP12011988 patent/ECSP12011988A/es unknown
- 2012-06-21 CO CO12104387A patent/CO6551737A2/es active IP Right Grant
- 2012-06-21 CL CL2012001685A patent/CL2012001685A1/es unknown
- 2012-06-22 CR CR20120339A patent/CR20120339A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201200205A (es) | "analogo peptidico de oxintomodulina" | |
| DOP2012000176A (es) | Analogo peptidico de oxintomodulina | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| GT201200263A (es) | "nuevos peptidos y metodos para su preparacion y uso" | |
| GT200900304A (es) | "antagonistas ciclicos de peptido cxcr4" | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| CO7400885A2 (es) | Análogos de glucagón | |
| PE20151770A1 (es) | Compuesto peptidico | |
| PE20120914A1 (es) | Compuestos glucagon activo de receptor de gip | |
| PE20130338A1 (es) | Analogos del glucagon | |
| CL2020002574A1 (es) | Análogos novedosos de glp-1 | |
| MX355457B (es) | Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion. | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| AR081200A1 (es) | Formulaciones de insulina de accion prolongada | |
| BR112012027759A2 (pt) | Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso | |
| ZA201001556B (en) | Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof | |
| PE20120563A1 (es) | Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| ECSP11010877A (es) | Combinación de inhibidor de la proteasa ns3 de hcv con interferón y ribavirina | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением | |
| ES2542227T3 (es) | Tratamiento de complicaciones vasculares de diabetes | |
| CU23701A1 (es) | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i | |
| UY31888A (es) | Compuestos de 1,1-dióxido de [1,2,4,]tiadiazina |